


MEDICINAL PRODUCTS 2021

NEOGEN CORP Rank 2 of 52









MEDICINAL PRODUCTS 2021

NEOGEN CORP Rank 2 of 52



The relative strengths and weaknesses of NEOGEN CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEOGEN CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of NEOGEN CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 4.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 155%, being 210% points above the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	537,406
Assets, Non-Current	181,105
General and Administrative Expense	335,897
Goodwill	0
Liabilities, Current	48,489
Liabilities, Non-Current	5,391
Other Assets	0
Other Compr. Net Income	-8,069
Other Expenses	12,830
Other Liabilities	18,125
Other Net Income	4,782
Other Revenues	418,170
Property, Plant and Equipment, Net	78,671
Research and Development	14,750

Output Variable	Value in 1000 USD
Liabilities	72,005
Assets	797,182
Expenses	363,477
Revenues	418,170
Stockholders Equity	725,177
Net Income	59,475
Comprehensive Net Income	55,440
Economic Capital Ratio	155%

